losartan-potassium has been researched along with Leukemia--Myelomonocytic--Acute* in 2 studies
1 review(s) available for losartan-potassium and Leukemia--Myelomonocytic--Acute
| Article | Year |
|---|---|
Successful treatment of pure red cell aplasia after major ABO-incompatible T cell-depleted bone marrow transplantation with erythropoietin.
A 40-year-old woman with acute myeloid leukemia in first remission developed pure red cell aplasia after a T cell-depleted ABO-incompatible bone marrow transplant from her HLA-identical sister. She remained transfusion-dependent for 11 months despite conversion of the ABO blood group to donor type, and titers of anti-donor isohemagglutinin being undetectable. Treatment with erythropoietin resulted in rapid improvement of the anemia with no further need for transfusions up to 21 months post-transplant. This case suggests that erythropoietin may provide effective therapy for pure red cell aplasia after ABO-incompatible bone marrow transplantation without the additional risks of further immunosuppression. Topics: ABO Blood-Group System; Adult; Blood Group Incompatibility; Bone Marrow Transplantation; Erythropoietin; Female; Humans; Leukemia, Myelomonocytic, Acute; Lymphocyte Depletion; Red-Cell Aplasia, Pure; T-Lymphocytes; Transplantation, Homologous | 1997 |
1 other study(ies) available for losartan-potassium and Leukemia--Myelomonocytic--Acute
| Article | Year |
|---|---|
Resistant pure red cell aplasia after allogeneic stem cell transplantation with major ABO mismatch treated by escalating dose donor leukocyte infusion.
We report a case of pure red cell aplasia (PRCA) following allogeneic stem cell transplantation (SCT) with major ABO mismatch which proved resistant to all standard treatment options such as change in immunosuppressive treatment, high-dose erythropoietin (EPO) or plasma exchange. We therefore proceeded to administer five cycles of Rituximab therapy, without success. Finally, escalating doses of donor-derived leukocyte infusion (DLI) resolved the PRCA of our patient 415 d after bone-marrow transplantation (BMT) and 140 d after the first infusion of donor leukocytes. A review of the literature shows the efficacy of various treatments; the role of DLI and other treatment options are discussed. Furthermore, the underlying pathophysiological mechanisms especially with regard to the role of NK cells in alloreactivity after allogeneic SCT are explained. Topics: ABO Blood-Group System; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Blood Group Incompatibility; Blood Transfusion; Combined Modality Therapy; Cytarabine; Drug Resistance; Erythropoietin; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Killer Cells, Natural; Leukemia, Myelomonocytic, Acute; Leukocyte Transfusion; Male; Middle Aged; Plasmapheresis; Red-Cell Aplasia, Pure; Remission Induction; Rituximab; Transplantation, Homologous | 2004 |